What is the recommended medical management for a patient with basal inferior severe hypokinesis on echocardiogram after recent right coronary artery (RCA) stenting?

Medical Management After RCA Stenting with Basal Inferior Severe Hypokinesis

You must be on dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor for at least 12 months following drug-eluting stent placement in the RCA, combined with guideline-directed medical therapy for heart failure and secondary prevention. 1

Core Antiplatelet Regimen

DAPT is mandatory and consists of:

• Aspirin (indefinitely)
• P2Y12 inhibitor for 12 months minimum 1

The choice of P2Y12 inhibitor depends on your clinical presentation:

• If this was an acute coronary syndrome (STEMI/NSTEMI): Use ticagrelor or prasugrel (preferred over clopidogrel) 1
• If this was elective/stable CAD: Clopidogrel is standard, though ticagrelor/prasugrel may be considered if prior stent thrombosis occurred 1

Critical caveat: Never discontinue DAPT prematurely in the first 12 months—this is an independent predictor of stent thrombosis and mortality 1. The case evidence shows that even temporary interruption carries substantial risk.

Heart Failure Management for Regional Wall Motion Abnormality

Given the severe hypokinesis of the basal inferior wall, you likely have some degree of left ventricular dysfunction. Initiate or optimize:

• ACE inhibitor or ARB (reduce remodeling, improve mortality)
• Beta-blocker (reduce mortality post-MI, control heart rate) 1
• Aldosterone antagonist if LVEF ≤40% and symptomatic
• Statin (high-intensity for secondary prevention)

The basal inferior hypokinesis indicates RCA territory involvement, which commonly affects right ventricular function as well 2, 3. Request assessment of:

• Right ventricular function (TAPSE, RVFAC on echo) 3
• Global left ventricular ejection fraction
• Presence of any LV thrombus (requires anticoagulation if present) 1

Monitoring for Complications

Watch specifically for:

1. Right ventricular involvement: Basal inferior hypokinesis of the RV occurs in 40.9% of inferior MI cases and predicts worse outcomes 2. Signs include elevated JVP, hypotension, clear lungs despite low cardiac output.

2. LV thrombus formation: Severe regional wall motion abnormalities, especially with akinetic segments, increase thrombus risk. If thrombus develops, add anticoagulation (warfarin or DOAC) for up to 6 months with repeat imaging 1. This creates a triple therapy situation (aspirin + P2Y12 inhibitor + anticoagulant)—minimize duration to 1-3 months if bleeding risk is acceptable 1.

3. Recurrent ischemia: The presence of severe hypokinesis suggests significant myocardial damage. If angina recurs or heart failure worsens, consider viability testing (stress echo, cardiac MRI, or PET) to assess for hibernating myocardium in other territories 4.

Risk Stratification

Unfavorable prognostic indicators in your situation include: 2

• Visualization of >4 segments with impaired contractility
• Decreased global circumferential strain
• Need for multi-vessel stenting
• Reduced LVEF
• ECG signs of RV infarction

If multiple high-risk features are present, closer follow-up (2-4 weeks post-discharge) is warranted rather than standard 4-6 week intervals.

Bleeding vs. Ischemic Risk Balance

The guidelines emphasize balancing bleeding and ischemic risk 1. If you have high bleeding risk (elderly, prior GI bleeding, anemia, renal dysfunction):

• Continue DAPT for minimum 6 months (not 12) if tolerated
• Consider proton pump inhibitor for GI protection
• Avoid NSAIDs completely

If acute bleeding occurs: Do not stop both antiplatelet agents simultaneously—this dramatically increases stent thrombosis risk. Manage the bleeding source interventionally while maintaining at least single antiplatelet therapy 1.

Practical Algorithm

At discharge:

1. Aspirin + P2Y12 inhibitor (ticagrelor/prasugrel if ACS, clopidogrel if stable)
2. Beta-blocker
3. ACE inhibitor/ARB
4. High-intensity statin
5. PPI if bleeding risk factors present

At 1 month:

• Assess symptoms, medication tolerance
• Repeat echo if initial LVEF was reduced or if new symptoms

At 6-12 months:

• Repeat echo to assess for recovery of wall motion
• If LVEF remains reduced, continue aldosterone antagonist
• Continue DAPT through 12 months minimum

After 12 months:

• Continue aspirin indefinitely
• Stop P2Y12 inhibitor (or consider extended DAPT if very high ischemic risk and low bleeding risk)

The severe hypokinesis indicates substantial myocardial injury, so aggressive secondary prevention and close monitoring for heart failure progression are essential alongside the mandatory antiplatelet therapy.